<img height="1" width="1" style="display:none" src="https://www.facebook.com/tr?id=799546403794687&amp;ev=PageView&amp;noscript=1">
Blogs

Pharmacy News and Stories

Oncology

Faculty    Cancer    Pharmacy    Oncology

Oncology Pharmacists Share Cancer Expertise in Nigeria

NOTE: This article originally appeared in Pharmacy Practice News; Dave Doolittle, writer.

Cindy O’Bryant, PharmD, didn’t know quite what to expect in the days leading up to a trip to Nigeria late last year that was designed to help strengthen cancer treatment and care in the African nation. Although she has met several Nigerian healthcare professionals and students as a clinical pharmacy professor at the University of Colorado Anschutz Skaggs School of Pharmacy and Pharmaceutical Sciences she had no first-hand knowledge of how her colleagues there treated cancer patients.


Author Guest Contributor | Publish Date May 03, 2022
Full Story

Pharmacy    Oncology

Fulbright Sends O'Bryant to Nigeria

Dr. Cindy O’Bryant, PharmD, Professor in the Department of Clinical Pharmacy, received a Fulbright Specialist Program Scholar Award. A program of the U.S. Department of State, the Fulbright Specialist Program is a unique opportunity for U.S. academics and established professionals to engage in two to six-week, project-based exchanges at host institutions across the globe. On November 27, Dr. O’Bryant left the U.S. for Nigeria with other oncology pharmacists to share her knowledge and experience in cancer care to advance pharmacy oncology practice. She made time to answer questions before her trip about her award, what she expects from the field, and what she hopes to share with medical professionals in Nigeria.


Author Jordan Kellerman | Publish Date December 01, 2021
Full Story

School of Pharmacy In the News

KSUT

Colorado law empowers students in public and charter schools to be Naloxone first responders

news outletKSUT
Publish DateMay 02, 2024

Students are empowered to carry and administer Narcan regardless of whether a school district has a policy in place and without permission from schools. The new law also resolves some legal gray areas.
 
“The question was, are the schools immune?” said José Esquibel, director of the Colorado Consortium for Prescription Drug Abuse Prevention. “Schools wanted to know, ‘Are we going to be liable for something that occurs on school campuses, and could a parent or someone else initiate a lawsuit against the school?’”

Full Story
American Association of Colleges of Pharmacy

The Intricacies of Aging

news outletAmerican Association of Colleges of Pharmacy
Publish DateMay 02, 2024

Dr. Sunny Linnebur, who practices at a primary care clinic serving patients over 75, is focused on drug safety and deprescribing. “What I want students to understand is when you give a medication to a 40-year-old it has one outcome, but for an 80-year-old it can have a completely different outcome,” she said. “There are adverse reactions that can lead to hospitalization. We have to be careful and thoughtful about medications in older adults.”

Full Story
CNN

Here’s what marijuana researchers have to say about 420 or ‘weed day’

news outletCNN
Publish DateMay 01, 2024

“I worry when people are in an enclosed space because new data is beginning to show that secondhand marijuana smoke may be just as dangerous as the primary smoke,” Robert Page, PharmD, said. “Like tobacco, cannabis affects the central nervous system, and there are side effects which tend to primarily be cardiovascular in nature.”

Full Story
Infectious Disease Special Edition

Don’t Let Hypersensitivity Fears Discourage Cefazolin Use in Joint Arthroplasty

news outletInfectious Disease Special Edition
Publish DateMay 01, 2024

Meghan N. Jeffres, PharmD, says that her new study demonstrates that cefazolin should be considered first-line regardless of penicillin allergy. “Prosthetic joint infections, in particular, are very bad, with a five-year mortality rate of 30 percent, and preventing them should be high on our list. Our study shows that cefazolin is significantly better than clindamycin and/or vancomycin in achieving that goal, without added HSR risk,” she said.

Full Story